TransMedics Posts 37% Revenue Growth in 2025, Eyes Expansion in Europe and Kidney Program
Event summary
- TransMedics reported $605.5 million in full-year 2025 revenue, up 37% from 2024, driven by increased OCS utilization and logistics services.
- Net income surged to $190.3 million in 2025, including an $82.8 million tax benefit from deferred tax assets.
- Completed 5,139 U.S. OCS cases in 2025, a 38% increase from 2024, with 22 owned aircraft as of December 31, 2025.
- Signed a long-term lease for new global headquarters in Somerville, Mass., and acquired adjacent land for a fully integrated campus.
- Received FDA approval for OCS ENHANCE Heart and DENOVO Lung trials.
The big picture
TransMedics' strong 2025 performance reflects the growing adoption of its Organ Care System and National OCS Program. The company's strategic focus on expanding into Europe and launching the OCS Kidney program positions it to capitalize on the increasing demand for advanced organ transplant technologies. The recent FDA approvals further solidify its leadership in the portable extracorporeal warm perfusion space.
What we're watching
- Execution Risk
- Whether TransMedics can sustain its growth trajectory while expanding into Europe and launching the OCS Kidney program.
- Regulatory Compliance
- How the FDA approvals for the OCS ENHANCE Heart and DENOVO Lung trials will impact future regulatory pathways.
- Operational Scaling
- The pace at which TransMedics can scale its manufacturing and logistics capabilities to meet increasing demand.
Related topics